GlassScriptPhysician profile
Amy Jo Purvis
NPI 1467708156
$3,492.88
in general payments reported to CMS, 2019-2025
23 companies · $17.02 in 2025
The $17.02 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,082 · 2022: $656 · 2023: $1,101 · 2024: $637 · 2025: $17.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,754.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $488.00 | 2022-2023 | Elzonris |
| Seagen INC. | $397.75 | 2021-2023 | Tukysa |
| Glaxosmithkline, LLC. | $387.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $290.70 | 2022-2023 | Calquence |
| Beigene USA, INC. | $277.01 | 2023-2024 | Brukinsa |
| Celgene Corporation | $228.37 | 2022-2025 | Reblozyl, Onureg, Pomalyst |
| Clovis Oncology, INC. | $167.24 | 2021 | |
| Janssen Biotech, INC. | $158.41 | 2022-2024 | Darzalex |
| Ipsen Biopharmaceuticals, INC | $134.71 | 2024 | Tazverik |
| Janssen Scientific Affairs, LLC | $122.58 | 2023 | Tecvayli |
| Abbvie INC. | $118.14 | 2024 | |
| Genmab U.S., INC. | $118.03 | 2021 | |
| Jazz Pharmaceuticals INC. | $115.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.69 | 2022 | |
| Lilly USA, LLC | $89.07 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $88.34 | 2023 | Monjuvi |
| Merck Sharp & Dohme LLC | $47.88 | 2023 | Lynparza, Keytruda |
| Incyte Corporation | $39.95 | 2023-2024 | Jakafi |
| Gilead Sciences, INC. | $33.44 | 2021-2022 | |
| Blueprint Medicines Corporation | $23.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.45 | 2023 | |
| Eisai INC. | $17.36 | 2023 | |
| Amgen INC. | $16.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jo Purvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.